SCHEMBL31380900

SCHEMBL31380900

COc1ccc(-c2ccn3ccnc3c2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ PKM P14618 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ PDGFRB P09619 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ ALDH1A3 P47895 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31380975 0.83 ALDH1A3 (0.56) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL14826051 0.81 PIK3C3 (0.51) PIK3C3SRCKDRFLT3DYRK1A
SCHEMBL29889235 0.74 TUBB4A (0.46) SMN1; SMN2MAPTPIK3C3GSK3BCDK2
SCHEMBL21364619 0.73 PIK3C3 (0.46) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL3321465 0.73 FLT3 (0.48) KDM4EPIK3C3SRCKDRFLT3
SCHEMBL31380997 0.73 PIK3C3 (0.49) RAB9ANPC1PIK3C3SRCKDR
SCHEMBL29303281 0.73 PIK3CD (0.44) PIK3C3GSK3BCDK2SRCKDR
SCHEMBL8840880 0.73 PDE4A (0.67) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL14525861 0.73 L3MBTL1 (0.51) ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2
SCHEMBL2657868 0.73 CCR1 (0.44) KDM4ERAB9ASMN1; SMN2NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity UNIV DE VELENCIA (ES) 2026-03-12 — — US claimed
WO-2025003545-A1 DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY UNIVERSITAT DE VALÈNCIA (ES) 2025-01-02 — — WO claimed
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity UNIV DE VELENCIA (ES) 2026-03-12 — — US disclosed
WO-2025003545-A1 DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY UNIVERSITAT DE VALÈNCIA (ES) 2025-01-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070905-A1 Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity IL1A, IL6, IL1B ALDH1A1 246/4885KDM4E 2088/4885HPGD 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback